In the realm of toxicology, prodrugs present both opportunities and challenges. On one hand, they can reduce toxicity by minimizing exposure of non-target tissues to the active drug. For example, prodrugs of chemotherapy agents can limit toxic effects on healthy tissues. On the other hand, the metabolic conversion of a prodrug can sometimes produce toxic metabolites, leading to unexpected toxicological issues.
